

EVALUATION OF A PEER AND NURSE LED PRIMARY HEALTH CARE AND HEPATITIS C TESTING/TREATMENT MODEL WITHIN A PEER- BASED NEEDLE AND SYRINGE PROGRAM

AUTHORS: Hadlow B
McNaughton T, Doab
A, Gilliver R, Silins E,
Pepolim L, Harrod M ,
Henderson C, Read P.

Kirketon Road Center,
Sydney, NSW

NSW Users and AIDS
Association
(NUAA), Sydney

NDARC, UNSW
Australia, Sydney,
NSW

Kirby Institute,
UNSW Australia,
Sydney, NSW

**KRC HEALTH
FOR ALL!**



ACKNOWLEDGEMENTS

- Before we begin, with absolute respect I acknowledge this is and will always be aboriginal land. I come to you from land of the Gadigal People of the Eora nation and acknowledge elders past present and future.
- As a Peer it's important for me to acknowledge community. This is my community, the community of people who use drugs illicitly.

DESCRIPTION OF MODEL OF CARE/INTERVENTION

- We wanted to know what our clients understood of a Peer and Nurse Led Model of Care.
- As people accessed the clinic, we gave them a questionnaire to fill out.
- Questions explored peers overall experience, level of satisfaction and general understanding of or services.

EFFECTIVENESS

- Almost 99% of participants knew that we offered testing and treatment for Hepatitis C
- Word of mouth was the most common response when asked how consumers knew about our clinic.
- The two main reasons people gave for attending were confidentiality and provision of a non-judgmental service.
- The convenience of a 'One Stop Shop' or NSP and walk in clinic also rated very highly.
- Crucially, people stated that connection with a peer gave them more trust in us and the healthcare we provide.

CONCLUSION AND NEXT STEPS.

- These findings are important so we can continue to scale-up the peer- nurse partnership and deliver an acceptable and equitable model of care.
- In a community who traditionally feel excluded or separate from healthcare we have trust and a solid reputation. That allows access where previously there was none.
- This model of care is important in maintaining the trajectory towards elimination of hepatitis C.

DISCLOSURE OF INTEREST STATEMENT

- Doctor Phillip Read has received research funding from Gilead Sciences, as well as institutional and individual honoraria from Gilead Sciences, Abbvie and MSD.